English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  A High-Throughput Fluorescence Polarization-Based Assay for the SH2 Domain of STAT4

Berg, A., Gräber, M., Schmutzler, S., Hoffmann, R., & Berg, T. (2022). A High-Throughput Fluorescence Polarization-Based Assay for the SH2 Domain of STAT4. Methods and protocols, 5(6): 93. doi:10.3390/mps5060093.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Berg, Angela1, Author
Gräber, Martin2, Author           
Schmutzler, Sebastian1, Author
Hoffmann, Ralf1, Author
Berg, Thorsten1, Author
Affiliations:
1external, ou_persistent22              
2Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565172              

Content

show
hide
Free keywords: POLO-BOX DOMAIN; MITOCHONDRIA-DERIVED ACTIVATOR; SMALL-MOLECULE MIMETICS; X-LINKED INHIBITOR; SIGNAL TRANSDUCER; BINDING ASSAY; KINASE 1; TRANSCRIPTION; APOPTOSIS; POTENTBiochemistry & Molecular Biology; assay development; fluorescence polarization; protein-protein interactions; SH2 domain; STAT4;
 Abstract: The signal transducer and activation of transcription (STAT) proteins are a family of Src homology 2 (SH2) domain-containing transcription factors. The family member STAT4 is a mediator of IL-12 signalling and has been implicated in the pathogenesis of multiple autoimmune diseases. The activity of STAT4 requires binding of phosphotyrosine-containing motifs to its SH2 domain. Selective inhibitors of the STAT4 SH2 domain have not been published to date. Here, we present a fluorescence polarization-based assay for the identification of inhibitors of the STAT4 SH2 domain. The assay is based on the interaction between the STAT4 SH2 domain and the fluorophore-labelled peptide 5-carboxyfluorescein-GpYLPQNID (K-d = 34 +/- 4 nM). The assay is stable with respect to DMSO concentrations of up to 10% and incubation times of at least 8 h. The Z'-value of 0.85 +/- 0.01 indicates that the assay is suited for use in high-throughput screening campaigns aimed at identifying new therapeutic modalities for the treatment of autoimmune diseases.

Details

show
hide
Language(s): eng - English
 Dates: 2022-11-23
 Publication Status: Published online
 Pages: 10
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: ISI: 000902537300001
DOI: 10.3390/mps5060093
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Methods and protocols
  Abbreviation : M&Ps
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Basel, Switzerland : MDPI
Pages: - Volume / Issue: 5 (6) Sequence Number: 93 Start / End Page: - Identifier: ISSN: 2409-9279
CoNE: https://pure.mpg.de/cone/journals/resource/2409-9279